SCHEMBL12907428

SCHEMBL12907428

Cc1n[nH]c2cc(-c3cccc(C(F)(F)F)c3)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
IKBKB O14920 1/20 0.50
KDR P35968 2/20 0.49
PLK4 O00444 1/20 0.49
AURKA O14965 1/20 0.49
ROCK2 O75116 1/20 0.49
CHEK2 O96017 1/20 0.49
EGFR P00533 1/20 0.49
NTRK1 P04629 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
CSF1R P07333 1/20 0.49
LYN P07948 1/20 0.49
KIT P10721 1/20 0.49
FLT1 P17948 1/20 0.49
EPHA2 P29317 1/20 0.49
FLT4 P35916 1/20 0.49
FLT3 P36888 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907422 0.87 GSK3B (0.55) KDRPLK4AURKAROCK2CHEK2
SCHEMBL12907194 0.84 PDPK1 (0.66) HDAC1HDAC2HDAC8IKBKBKDR
SCHEMBL13122227 0.83 TRPA1 (0.55) TRPA1MAP2K4MAPK1MAPK6MAPKAPK5
SCHEMBL12907457 0.80 JAK2 (0.67) KDRAURKAAURKBPDPK1MKNK1
SCHEMBL29550433 0.80 KDM4E (0.50) IKBKBPIM1NOTUMIDO1
SCHEMBL22775716 0.80 KDM4E (0.50) IKBKBPIM1NOTUMIDO1
SCHEMBL12907435 0.78 CHEK1 (0.58) KDRJAK3PDPK1JAK2GSK3B
SCHEMBL12907442 0.76 TRPA1 (0.60) TRPA1MAPK1
SCHEMBL12907438 0.76 GSK3B (0.54) PDPK1NOTUMJAK2GSK3BPOLB
SCHEMBL12907220 0.75 JAK2 (0.65) IKBKBKDRPLK4AURKAROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed